US 9,956,270 B2 · Pharmaceutical composition comprising bee venom-phospholipase A2 (BV-PLA2) for treating or preventing diseases related to degradation of abnormal regulatory T cell activity

Abstract

The present invention relates to a pharmaceutical composition for treating or preventing a disease related to abnormal suppression of regulatory T cell activity comprising a polypeptide comprising a bee venom-PLA2 amino acid sequence exclusive of a leader sequence as an active ingredient. The secretory bee venom-phospholipase A2 of the present invention activates a regulatory T cell and suppress a differentiation of Th1/Th7. Therefore, the present polypeptide can be used as a pharmaceutical composition for treating or preventing a disease related to abnormal suppression of regulatory T cell activity, i.e. autoimmune diseases, allergic diseases, or neurodegenerative diseases.

Claims1

Dependent claims

A method for treating rheumatoid arthritis, multiple sclerosis or psoriasis comprising:

administering an effective amount of a composition comprising an isolated polypeptide to a subject having rheumatoid arthritis, multiple sclerosis or psoriasis, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO:6.

Dependencies are inferred from the claim text.

Facts

Application

15/387,579Filed 21 Dec 2016 · division

Priority

KR 10-2012-001992527 Feb 2012

Published

US 2017/0173120 A122 Jun 2017

Granted

1 May 2018

Term ends

Not estimatedThe source records don’t support an estimate.

Classification12 codes

A61K 38/465
Hydrolases: acting on ester bonds , e.g. lipases, ribonucleases
A61K 9/0019
Galenical forms characterised by the site of application: injectable compositions; Intramuscular, intravenous, arterial, subcutaneous…
A61K 35/63
Materials from animals other than mammals: arthropods
A61K 35/64
Arthropods: insects, e.g. bees, wasps or fleas

Family

PCT/KR2012/004394Parent of this division · filed 4 Jun 2012

US 2017/0173120 A1Pre-grant publication · published 22 Jun 2017

Application14/381,095Parent of this division

US 9,526,767 B2Parent of this division

US 2015/0150951 A1Published application

US 9,956,270 B2This patent

From the US filing history. Foreign family members aren’t listed.

Pharmaceutical composition comprising bee venom-phospholipase A2 (BV-PLA2) for treating or preventing diseases related to degradation of abnormal regulatory T cell activity

Life of this patent

Pharmaceutical composition comprising bee venom-phospholipase A2 (BV-PLA2) for treating or preventing diseases related to degradation of abnormal regulatory T cell activity

Life of this patent

Abstract

Claims1